Weekly Recap: Cipla Ltd Q2 revenue, profit decline and FDA VAI Verna Goa
NiveshIQ
NSE: CIPLA · Healthcare
Cipla Ltd.
₹1,387.00▲ ₹8.10 (+0.59%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on CIPLA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Cipla Ltd.
Cipla Limited, headquartered in Mumbai, is a diversified pharmaceutical company that designs, manufactures, and distributes generic and branded generic medicines, vaccines, and active pharmaceutical ingredients across India, the United States, South Africa, and other international markets. In Q2 FY27, India revenue surged to ₹28,068 crore, driven by strong demand for cardiovascular, respiratory, and oncology products, while margin pressure from raw material costs and pricing competition weighed on profitability. The company’s biosimilars and specialty segments continue to expand, with recent approvals for oncology biosimilars boosting its pipeline. Cipla faces exposure to ongoing NPPA litigation, which has impacted consolidated EBITDA and net profit, leading to a 1.85% share price decline
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹25,774 Cr +13.28% | ₹27,548 Cr +6.88% | ₹28,163 Cr +2.23% |
| EBITDA Margin | 24.41% | 25.87% | 20.89% |
| Net Profit | ₹4,122 Cr +47.10% | ₹5,273 Cr +27.93% | ₹3,879 Cr -26.43% |
| EPS | ₹51.05 | ₹65.29 | ₹48.03 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
CIPLA Share Price Today - Cipla on NSE/BSE
Cipla Limited (CIPLA.NS) Seasonal Returns Chart - Yahoo Finance
🔒
+ 3 more stories about Cipla Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹7, 404 Cr, PAT ₹878 Cr, EPS ₹10.86, EBITDA margin 18.7%. Growth context: revenue YoY -2.4%, PAT YoY -35.1%, revenue QoQ +4.0%, PAT QoQ +11.2%. Street verdict: strong miss.
Management highlights product launches, approvals, therapy‑mix improvement, order wins, deal pipeline, and backlog build...
FY26 (last completed FY): revenue ₹28, 163 Cr, PAT ₹3, 879 Cr, EBITDA margin 20.9%, EPS ₹48.03. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for CIPLA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track CIPLA alongside your other holdings
Unlock full CIPLA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Cipla Ltd.?
NiveshIQ detects active intelligence signals for Cipla Ltd. (CIPLA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Cipla Ltd.?
Cipla Ltd. operates in the Healthcare sector with a market capitalisation of ₹10,888,909.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.